MA42419B1 - Méthode de traitement de l'encéphalopathie hépatique - Google Patents

Méthode de traitement de l'encéphalopathie hépatique

Info

Publication number
MA42419B1
MA42419B1 MA42419A MA42419A MA42419B1 MA 42419 B1 MA42419 B1 MA 42419B1 MA 42419 A MA42419 A MA 42419A MA 42419 A MA42419 A MA 42419A MA 42419 B1 MA42419 B1 MA 42419B1
Authority
MA
Morocco
Prior art keywords
treatment
hepatic encephalopathy
encephalopathy
hepatic
biotin
Prior art date
Application number
MA42419A
Other languages
English (en)
Other versions
MA42419A (fr
Inventor
Frédéric Sedel
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of MA42419A publication Critical patent/MA42419A/fr
Publication of MA42419B1 publication Critical patent/MA42419B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation de la biotine à une dose quotidienne d'au moins 100 mg pour le traitement de l'encéphalopathie hépatique.
MA42419A 2016-07-29 2017-07-28 Méthode de traitement de l'encéphalopathie hépatique MA42419B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305989.2A EP3275439A1 (fr) 2016-07-29 2016-07-29 Procédé de traitement de l'encéphalopathie hépatique
PCT/EP2017/069194 WO2018020010A1 (fr) 2016-07-29 2017-07-28 Méthode de traitement de l'encéphalopathie hépatique

Publications (2)

Publication Number Publication Date
MA42419A MA42419A (fr) 2018-05-16
MA42419B1 true MA42419B1 (fr) 2019-11-29

Family

ID=56618106

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42419A MA42419B1 (fr) 2016-07-29 2017-07-28 Méthode de traitement de l'encéphalopathie hépatique

Country Status (23)

Country Link
US (2) US10117854B2 (fr)
EP (2) EP3275439A1 (fr)
JP (1) JP2019522030A (fr)
KR (1) KR20190034550A (fr)
AU (1) AU2017303346A1 (fr)
BR (1) BR112019001178A2 (fr)
CA (1) CA3031302A1 (fr)
CY (1) CY1122348T1 (fr)
DK (1) DK3319601T3 (fr)
EA (1) EA201990413A1 (fr)
ES (1) ES2751154T3 (fr)
HK (1) HK1254833B (fr)
HR (1) HRP20191798T1 (fr)
HU (1) HUE046590T2 (fr)
IL (1) IL264460B (fr)
LT (1) LT3319601T (fr)
MA (1) MA42419B1 (fr)
ME (1) ME03520B (fr)
PL (1) PL3319601T3 (fr)
PT (1) PT3319601T (fr)
RS (1) RS59300B1 (fr)
SI (1) SI3319601T1 (fr)
WO (1) WO2018020010A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275439A1 (fr) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Procédé de traitement de l'encéphalopathie hépatique
MX2018004788A (es) * 2018-04-18 2019-10-21 Alparis Sa De Cv Nuevas fases solidas de rifaximina.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788304B2 (ja) * 1988-03-05 1995-09-27 三生製薬株式会社 高アンモニア血症治療剤
US5814650A (en) * 1992-09-28 1998-09-29 Lifegroup S.P.A. Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions
DE20202562U1 (de) * 2002-02-19 2002-05-23 Orthomol Pharmazeutische Vertr Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
WO2011077239A2 (fr) 2009-12-23 2011-06-30 Lupin Limited Compositions pharmaceutiques d'ilopéridone à libération lente
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
WO2014177286A1 (fr) 2013-04-29 2014-11-06 Assistance Publique - Hopitaux De Paris Biotine pour son utilisation dans le traitement d'une adrénoleucodystrophie liée à l'x
EP3072513A1 (fr) 2015-03-26 2016-09-28 Medday Biotin pour le traitement de la sclérose latérale amyotrophique
CN105614851A (zh) * 2015-12-27 2016-06-01 劲膳美生物科技股份有限公司 肝性脑病医学配方食品
EP3275439A1 (fr) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Procédé de traitement de l'encéphalopathie hépatique

Also Published As

Publication number Publication date
JP2019522030A (ja) 2019-08-08
LT3319601T (lt) 2019-11-11
MA42419A (fr) 2018-05-16
US10117854B2 (en) 2018-11-06
US20180214417A1 (en) 2018-08-02
US20190070150A1 (en) 2019-03-07
PT3319601T (pt) 2019-09-18
WO2018020010A1 (fr) 2018-02-01
HUE046590T2 (hu) 2020-03-30
CA3031302A1 (fr) 2018-02-01
EP3275439A1 (fr) 2018-01-31
PL3319601T3 (pl) 2020-06-29
SI3319601T1 (sl) 2019-11-29
HK1254833B (zh) 2020-05-22
EP3319601B1 (fr) 2019-08-28
KR20190034550A (ko) 2019-04-02
BR112019001178A2 (pt) 2019-04-30
IL264460A (en) 2019-02-28
CY1122348T1 (el) 2021-01-27
ES2751154T3 (es) 2020-03-30
EP3319601A1 (fr) 2018-05-16
DK3319601T3 (da) 2019-11-18
US10328059B2 (en) 2019-06-25
EA201990413A1 (ru) 2019-06-28
RS59300B1 (sr) 2019-10-31
ME03520B (fr) 2020-04-20
AU2017303346A1 (en) 2019-01-31
IL264460B (en) 2021-06-30
HRP20191798T1 (hr) 2019-12-27

Similar Documents

Publication Publication Date Title
MA55021A (fr) 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression
MA41013B1 (fr) Compositions comprenant des souches bactériennes
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA41060B1 (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471A (fr) Compositions comprenant des souches bactériennes
MA41010B1 (fr) Compositions comprenant des souches bactériennes
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA47719A (fr) Esketamine pour le traitement de la dépression
MA38827A1 (fr) Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives
MA39984B1 (fr) Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA51203A (fr) Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
MA45999A (fr) Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
MA46548B1 (fr) Fsh pour le traitement de l'infertilité
MA43800A (fr) Octréotide par voie orale pour le traitement de maladies
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial
MA42419B1 (fr) Méthode de traitement de l'encéphalopathie hépatique
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
MA41809B1 (fr) Biotine pour le traitement de la sclérose latérale amyotrophique
FR3019465B1 (fr) Composition hyperosmolaire d'acide hyaluronique et son utilisation pour le traitement de l'oedeme corneen